Toggle menu

SNAP40 Study

Start date:
September 2017
End date:
December 2017
Co-ordinated by:
EMERGE
Main trial site:
Royal Infirmary of Edinburgh

SNAP40-ED: Detection of physiological deterioration by the SNAP40 wearable device compared to standard monitoring devices in the Emergency Department.

SNAP40 is a device that monitors vital signs. It is small, portable and has no leads or wires, allowing for patients vital signs to be continuously monitored anywhere in the department. The device is smaller than most mobile phones, and is held within a blue casing attached to an armband (please see image). When fitted to a patient’s arm, the device will continuously monitor their vital signs whilst they are in the Emergency Department.

SNAP40 uses artificial intelligence algorithms to analyse data provided by its sensors in order to recognise indicators of health deterioration. The raw data collected by the sensors is converted into vital signs, which are analysed for signs of deterioration. An alert will be sent to staff if the device detects any signs of deterioration in the patient’s readings.

Funding: SNAP40

Sponsor: SNAP40, Forth Street, Edinburgh (UK)

Setting: This is a single centre study being co-ordinated from Edinburgh.

Chief Investigator

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

Polly Black

Senior Research Nurse

Alison Grant

Senior Research Nurse

Mary Morrissey

Senior Research Nurse

Related news

Exciting new trial: SNAP40

Exciting new trial: SNAP40

10 Apr 2017 | Megan McGrath

EMERGE will soon begin recruitment to the new SNAP40 trial which will compare the new SNAP40 device with standard monitoring devices in the Emergency Department.

Read more

More EMERGE Trials

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)